5 succinct key points:
- We discovered a statistically significant association between head and
facial lesions and the diagnosis of PHACE syndrome.
- 98% of our patients received a daily propanolol dose of 2 mg/kg, and
the average duration of propranolol treatment was approximately 11
months.
- Propranolol treatment yielded a positive response in 97% of our
patients, with 80% experiencing nearly complete or complete
improvement during the initial treatment cycle.
- The likelihood of residual lesion proliferation is higher when
propranolol therapy is discontinued at earlier stages of propanolol
response compared to complete response. This finding underscores the
importance of early intervention and vigilant post-treatment
monitoring to prevent regrowth.
- An intriguing aspect of our study is the potential role of a family
history of hemangiomas or cardiac abnormalities as a risk factor for
requiring a second propranolol cycle.